Drug Information
Drug (ID: DG00342) and It's Reported Resistant Information
Name |
Pertuzumab
|
||||
---|---|---|---|---|---|
Synonyms |
Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Breast cancer [ICD-11: 2C60]
[1]
|
||||
Target | Erbb2 tyrosine kinase receptor (HER2) | ERBB2_HUMAN | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
TTD Drug ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Breast cancer [ICD-11: 2C60]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [1] | |||
Molecule Alteration | Missense mutation | p.V1676A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Notch signaling pathway | Regulation | hsa04330 | |
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [1] | |||
Molecule Alteration | Missense mutation | p.V1599M |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Notch signaling pathway | Regulation | hsa04330 | |
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [1] | |||
Molecule Alteration | Missense mutation | p.S1689P |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Notch signaling pathway | Regulation | hsa04330 | |
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Nras (NRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.V14A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Nras (NRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.F78L |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Nras (NRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.F28S |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Nras (NRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.A66T |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) | [1] | |||
Molecule Alteration | Missense mutation | p.V345A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) | [1] | |||
Molecule Alteration | Missense mutation | p.R90Q |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) | [1] | |||
Molecule Alteration | Missense mutation | p.R74Q |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: DNA mismatch repair protein Mlh1 (MLH1) | [1] | |||
Molecule Alteration | Missense mutation | p.A348V |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.V9A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.T2A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.S17N |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.Q61X |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.N26S |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.G12S |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.D54N |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.R216L |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.R216C |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.R186H |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.N203S |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.M206V |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.D214N |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Adenylate cyclase-stimulating G alpha protein (GNAS) | [1] | |||
Molecule Alteration | Missense mutation | p.D181G |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.V292E |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.R705G |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.L760F |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.K284E |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.I706T |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.G696E |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.A822V |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.V292M |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.P741S |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.G288D |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Epidermal growth factor receptor (EGFR) | [1] | |||
Molecule Alteration | Missense mutation | p.E711K |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Cadherin-1 (CDH1) | [1] | |||
Molecule Alteration | Missense mutation | p.A348V |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Cadherin-1 (CDH1) | [1] | |||
Molecule Alteration | Missense mutation | p.V345A |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Cadherin-1 (CDH1) | [1] | |||
Molecule Alteration | Missense mutation | p.R90Q |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. | |||
Key Molecule: Cadherin-1 (CDH1) | [1] | |||
Molecule Alteration | Missense mutation | p.R74Q |
||
Resistant Disease | HER2 positive breast cancer [ICD-11: 2C60.8] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Plasma | Blood | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Next-generation sequencing assay; Circulating-free DNA assay | |||
Experiment for Drug Resistance |
Positron emission tomography/Computed tomography assay | |||
Mechanism Description | Seven genes, including epidermal growth factor receptor (EGFR), G protein subunit alpha S (GNAS), HRas proto-oncogene (HRAS), mutL homolog 1 (MLH1), cadherin 1 (CDH1), neuroblastoma RAS viral oncogene homolog (NRAS), and NOTCH1, that only occurred mutations in the resistant group were associated with the resistance of targeted therapy. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.